Spero Therapeutics Inc
NASDAQ:SPRO

Watchlist Manager
Spero Therapeutics Inc Logo
Spero Therapeutics Inc
NASDAQ:SPRO
Watchlist
Price: 0.7824 USD 0.5% Market Closed
Market Cap: 42.7m USD

Net Margin
Spero Therapeutics Inc

3.3%
Current
-319%
Average
-7%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
3.3%
=
Net Income
3.5m
/
Revenue
106.5m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Spero Therapeutics Inc
NASDAQ:SPRO
42.5m USD
3%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
373.8B USD
8%
US
Amgen Inc
NASDAQ:AMGN
168.4B USD
12%
US
Gilead Sciences Inc
NASDAQ:GILD
138.9B USD
2%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
129.7B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
121.1B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
73.1B USD
31%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
32.9B EUR
38%

Spero Therapeutics Inc
Glance View

Market Cap
42.5m USD
Industry
Biotechnology

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. The company is headquartered in Cambridge, Massachusetts and currently employs 146 full-time employees. The company went IPO on 2017-11-02. The firm is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. Its lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide), is developed as the oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). The company is also developing SPR720 as a novel oral therapy product candidate for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections. The firm also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is being developed to treat MDR Gram-negative infections in the hospital setting.

SPRO Intrinsic Value
0.4611 USD
Overvaluation 41%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
3.3%
=
Net Income
3.5m
/
Revenue
106.5m
What is the Net Margin of Spero Therapeutics Inc?

Based on Spero Therapeutics Inc's most recent financial statements, the company has Net Margin of 3.3%.

Back to Top